Published in Proc Natl Acad Sci U S A on February 18, 1997
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature (2016) 3.06
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88
Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol (1998) 2.85
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2012) 2.84
Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A (2003) 2.83
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (1999) 2.43
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest (1999) 2.21
Transsynaptic progression of amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron (2010) 2.10
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A (2005) 1.91
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci (2008) 1.78
Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease. Cell Stem Cell (2009) 1.68
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Nat Med (2014) 1.63
Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol (2005) 1.61
Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med (2007) 1.55
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53
Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol (2000) 1.52
Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest (2002) 1.51
VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. J Cell Biol (2011) 1.50
Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron (2008) 1.49
Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.48
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 1.44
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem (2005) 1.44
Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci (2010) 1.44
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem (2011) 1.40
Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes. J Biol Chem (2008) 1.37
Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A (2003) 1.37
Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis (2009) 1.37
Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A (2012) 1.34
Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci (2011) 1.32
Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am J Pathol (1998) 1.30
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation. Proc Natl Acad Sci U S A (2000) 1.30
The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet (2014) 1.28
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 1.28
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement (2013) 1.22
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol (2010) 1.22
Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol (1998) 1.21
Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging (2004) 1.21
Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci U S A (2004) 1.20
Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci (2016) 1.19
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol (1999) 1.17
Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci (2007) 1.17
Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis (2010) 1.17
beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol (2001) 1.17
Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia (2010) 1.15
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol (2000) 1.13
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis (2007) 1.13
Bapineuzumab. Expert Opin Biol Ther (2010) 1.12
Distinct temporal and anatomical distributions of amyloid-β and tau abnormalities following controlled cortical impact in transgenic mice. PLoS One (2011) 1.12
Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat (2007) 1.11
Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad Sci U S A (2008) 1.09
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev (2008) 1.08
In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease. Biochem J (2001) 1.06
Mutations enhance the aggregation propensity of the Alzheimer's A beta peptide. J Mol Biol (2008) 1.06
Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci (2006) 1.05
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A (2007) 1.04
Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis (2011) 1.04
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. J Clin Invest (2006) 1.04
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging (2008) 1.03
PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A (2006) 1.02
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep (2013) 1.02
Inhibition of JNK by a peptide inhibitor reduces traumatic brain injury-induced tauopathy in transgenic mice. J Neuropathol Exp Neurol (2012) 1.02
Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am J Pathol (1999) 1.01
Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience (2007) 1.01
Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry (2014) 1.00
Faster forgetting contributes to impaired spatial memory in the PDAPP mouse: deficit in memory retrieval associated with increased sensitivity to interference? Learn Mem (2008) 1.00
Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis (2011) 1.00
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol (2004) 0.98
Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein. J Biol Chem (2012) 0.97
Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol (2000) 0.97
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) (2011) 0.96
Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease. Br J Pharmacol (2011) 0.96
CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease. PLoS One (2012) 0.96
Novel advances in shotgun lipidomics for biology and medicine. Prog Lipid Res (2015) 0.95
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Diagnosis of Alzheimer's disease. Arch Neurol (1985) 12.77
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron (1994) 6.41
Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science (1990) 4.91
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 4.09
Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science (1993) 3.95
Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 3.86
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem (1993) 3.52
Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology (1996) 3.29
Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 3.17
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci (1994) 2.81
The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J (1993) 2.66
Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem (1995) 1.95
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature (1993) 1.85
An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron (1994) 1.77
Cell-type and amyloid precursor protein-type specific inhibition of A beta release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. J Biol Chem (1995) 1.40
The use of statins: a case of misleading priorities? BMJ (1997) 13.35
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Nested retrotransposons in the intergenic regions of the maize genome. Science (1996) 12.95
Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA (2000) 10.91
Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res (2000) 10.78
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol (1998) 7.41
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature (1992) 7.16
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
Photorefractive keratectomy versus laser in situ keratomileusis for moderate to high myopia. A randomized prospective study. Ophthalmology (1998) 6.54
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev (1997) 5.49
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Comparative genome mapping of Sorghum and maize. Genetics (1992) 5.14
A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature (1988) 5.11
Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science (1990) 4.71
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis (1999) 4.67
Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis (1999) 4.59
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem (2001) 4.45
Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. JAMA (2001) 4.30
Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol (1992) 4.11
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci (1992) 4.10
Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst (2000) 4.09
Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci U S A (1988) 4.02
Appropriateness of the decision to transfer nursing facility residents to the hospital. J Am Geriatr Soc (2000) 3.99
The In-vitro Sensitivity of H. influenzae to Penicillin. Br Med J (1945) 3.97
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
The sounds from single motor units in a contracting muscle. J Physiol (1948) 3.75
How well does chart abstraction measure quality? A prospective comparison of standardized patients with the medical record. Am J Med (2000) 3.70
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Phospholipid:diacylglycerol acyltransferase: an enzyme that catalyzes the acyl-CoA-independent formation of triacylglycerol in yeast and plants. Proc Natl Acad Sci U S A (2000) 3.22
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
The Genetics of Platypoecilus. II. the Linkage of Two Sex-Linked Characters. Genetics (1929) 3.14
Influence of PAX6 gene dosage on development: overexpression causes severe eye abnormalities. Cell (1996) 3.01
US physician warns Canadians about privatization. CMAJ (1996) 2.95
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
Molecular cloning and expression of the mouse ornithine decarboxylase gene. Proc Natl Acad Sci U S A (1984) 2.83
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet (2001) 2.76
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci (1996) 2.69
Methanogenesis in a Thermophilic (58 degrees C) Anaerobic Digestor: Methanothrix sp. as an Important Aceticlastic Methanogen. Appl Environ Microbiol (1984) 2.69
The value of antibiotics in minor respiratory illness in children. A controlled trial. Med J Aust (1974) 2.65
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol (1995) 2.62
Occupational physical demands, knee bending, and knee osteoarthritis: results from the Framingham Study. J Rheumatol (1991) 2.56